SCHEMBL21749199

SCHEMBL21749199

Cc1nc2cc(-c3ccc(Cl)cc3)nn2c(N2CCC[C@@](C(=O)O)(C(C)C)C2)c1C(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.41
KDM4E B2RXH2 4/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
ALDH1A1 P00352 4/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
HTT P42858 2/20 0.41
ABCB1 P08183 5/20 0.41
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
ABCG2 Q9UNQ0 2/20 0.39
TP53 P04637 2/20 0.39
MAPT P10636 5/20 0.38
RXFP1 Q9HBX9 1/20 0.38
LMNA P02545 4/20 0.38
HSD17B10 Q99714 1/20 0.38
KMT2A Q03164 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
DPP4 P27487 1/20 0.36
DPP8 Q6V1X1 1/20 0.36
TSHR P16473 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21749208 1.00 HPGD (0.41) HPGDKDM4ESMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL20503094 1.00 HPGD (0.41) HPGDKDM4ESMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL21775866 0.91 DPP4 (0.39) HPGDKDM4ESMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL21775753 0.91 DPP4 (0.39) HPGDKDM4ESMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL21749191 0.91 DPP4 (0.39) HPGDKDM4ESMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL21775682 0.90 ALDH1A1 (0.41) HPGDKDM4ESMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL21774076 0.89 ABCG2 (0.40) HPGDKDM4ESMN1; SMN2ALDH1A1ABCB1
SCHEMBL21749160 0.89 ABCG2 (0.40) HPGDKDM4ESMN1; SMN2ALDH1A1ABCB1
SCHEMBL21749207 0.89 DGAT1 (0.43) HPGDKDM4ESMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL21775746 0.89 DGAT1 (0.43) HPGDKDM4ESMN1; SMN2ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10960007-B2 Pharmacologically active aryl-substituted pyrazolo[1,5-a]pyrimidine derivatives RICHTER GEDEON NYRT. (HU) 2021-03-30 US claimed
US-20200061068-A1 Pharmacologically Active Aryl-Substituted Pyrazolo[1,5-a]Pyrimidine Derivatives RICHTER GEDEON NYRT. (HU) 2020-02-27 US claimed
US-10960007-B2 Pharmacologically active aryl-substituted pyrazolo[1,5-a]pyrimidine derivatives RICHTER GEDEON NYRT. (HU) 2021-03-30 US disclosed
US-20200061068-A1 Pharmacologically Active Aryl-Substituted Pyrazolo[1,5-a]Pyrimidine Derivatives RICHTER GEDEON NYRT. (HU) 2020-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200061068-A1 Pharmacologically Active Aryl-Substituted Pyrazolo[1,5-a]Pyrimidine Derivatives GABRA5, P2RX5, P2RY1 HPGD 1684/4885KDM4E 2972/4885SMN1; SMN2 2642/4885
US-10960007-B2 Pharmacologically active aryl-substituted pyrazolo[1,5-a]pyrimidine derivatives GABRA5, P2RX5, P2RY1 HPGD 1684/4885KDM4E 2972/4885SMN1; SMN2 2642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.